Iovance Biotherapeutics (NASDAQ:IOVA)+8%- Shares gained after Health Canada granted conditional approval for its T-cell immunotherapy Amtagvi (lifileucel) to treat advanced melanoma, making it the first T-cell therapy approved for a solid tumor and the first option available in Canada for patients who have failed anti-PD-1 and targeted therapies. The company said it expects to authorize its first Canadian treatment center within months while advancing its ex-U.S. strategy, though the market authorization under the NOC/c pathway remains conditional pending confirmatory trial results. Watch-->IOVA Iovance Biotherapeutics, Inc. $2.61 0.10(+4.20%)12:54 PM 08/19/25 NASDAQ |$USD |Realtime
Tectonic Therapeutic TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45’s safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease (“PH-ILD”, Group 3 PH) to expand the therapeutic breadth of TX45 Complete results from Part A of the TX45 Phase 1b clinical trial presented at ESC Heart Failure 2025 confirmed TX45’s tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in subjects with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”) Part B of the TX45 Phase 1b clinical trial in subjects with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH-HFrEF”) completed enrollment; topline results are expected in early Q4’2025 Ongoing TX45 APEX Phase 2 clinical trial continues to enroll; topline results expected in 2026 This name has more insider buying than any other stk I can find. Yet all those goalposts are Q4 25' or 2026./ A question of timing..... TX2100 is expected to initiate a Phase 1 clinical trial in healthy volunteers in Q1’2026 Cash and cash equivalents were $287.4 million as of June 30, 2025, including the private placement net proceeds raised in February 2025, expected to provide cash runway into Q4’2028
SP500S&P 500 Index- Another 120+ and we will have to consider raising some cash./I think we can drift to 6,000 and still be Ok... As long as it is slow./ 6,413.76-35.39(-0.55%)1:35 PM 08/19/25
In support & good RS today. The problem is if $60 breaks to the downside there is no support until $48/ ODD Oddity Tech Ltd. $61.35-0.68(-1.10%)1:35 PM 08/19/25